Odronextamab (with Regeneron)
Relapsed/Refractory B-cell non-Hodgkin lymphomas
Phase 3 / Regulatory ReviewActive
Key Facts
Indication
Relapsed/Refractory B-cell non-Hodgkin lymphomas
Phase
Phase 3 / Regulatory Review
Status
Active
Company
About Orion
Orion Corporation is a well-established, publicly traded Finnish pharmaceutical company with a diversified business spanning human prescription medicines, self-care products, veterinary medicines, and active pharmaceutical ingredient manufacturing. Founded over 100 years ago, it has a strong commercial footprint, particularly in Europe, and a late-stage R&D pipeline concentrated in oncology and pain. The company's strategy balances internal R&D with external partnerships and leverages its integrated API manufacturing capabilities for competitive advantage.
View full company profile